Cachexia is a multifactorial syndrome related to unintentional weight loss and to loss of muscle and fat mass. In head and neck cancer (HNC) its incidence is important and not only related to a deficient intake of food due to the impact of the disease in the vital functions. A complex disturbance in the normal metabolism of the patient promotes a persistent inflammatory state and a shifting in the metabolism balance toward a catabolic predominance affecting primarily the skeletal muscle. This leads to severe impairment of the functional, emotional and social status and quality of life of the patients that will compromise response to treatment and the disease prognosis. Understanding this deleterious syndrome and mainly identifying it in early stages of the disease is of a major importance in achieving better outcomes to head and neck cancer patients. This study pretends to identify clinical aspects related to cachexia in HNC in a clinical perspective for application on the routine clinical practice. In our study, 30 HNC patients were enrolled and evaluated in terms of nutritional values (actual and loss of weight in the past 6 months, body mass index (BMI), nutritional risk index (NRI), malnutrition universal screening tool), serum biochemical markers (albumin, total proteins, cholesterol, triglycerides, urea, C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) and myostatin) and health related quality of life (HRQoL) evaluation (using European Organisation for the Research and Treatment of Cancer (EORTC) quality of life questionnaires (QLQ): EORTC QLQ-C30 and EORTC QLQ-HN43). A minimum follow-up of 48 months was considered for all patients. Our results showed that NRI is a good and sensitive index to identify cachexia. This index uses two parameters, one constitutional (loss of weight) and one biochemical (level of serum albumin). According to this criterion, 16 patients were assigned to the No-cachexia group and 14 patients to the Cachexia group. Significant differences in the constitutional and nutritional values between the two groups were found: the median weight loss was 4.44 kg in the No-cachexia group and 11.29 kg in the Cachexia group, while the BMI was 21.88 and 18.33, respectively. In terms of biochemical markers, significant low values of albumin and cholesterol in the Cachexia group were encountered when compared to the No-cachexia group. Regarding the inflammatory and cachexia biomarkers studied, the results show that patients in the Cachexia group had significantly higher levels of CRP and of the
References
[1]
Johnson, D.E., Burtness, B., Leemans, C.R., et al. (2020) Head and Neck Squamous Cell Carcinoma. Nature Reviews Disease Primers, 6, 92. https://doi.org/10.1038/s41572-020-00224-3
[2]
Du, E., et al. (2019) Long-Term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status. Laryngoscope, 129, 2506-2513. https://doi.org/10.1002/lary.27807
[3]
Pulte, D., et al. (2010) Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. Oncologist, 15, 994-1001. https://doi.org/10.1634/theoncologist.2009-0289
[4]
Orell-Kotikangas, H., et al. (2017) Cachexia at Diagnosis Is Associated with Poor Survival in Head and Neck Cancer Patients. Acta Oto-Laryngologica, 137, 778-785. https://doi.org/10.1080/00016489.2016.1277263
[5]
Lis, C.G., et al. (2012) Role of Nutritional Status in Predicting Quality of Life Outcomes in Cancer—A Systematic Review of the Epidemiological Literature. Nutrition Journal, 11, 27. https://doi.org/10.1186/1475-2891-11-27
[6]
Couch, M., et al. (2007) Cancer Cachexia Syndrome in Head and Neck Cancer Patients: Part I. Diagnosis, Impact on Quality of Life and Survival, and Treatment. Head Neck, 29, 401-411. https://doi.org/10.1002/hed.20447
[7]
Couch, M.E., et al. (2015) Cancer Cachexia Update in Head and Neck Cancer: Definitions and Diagnostic Features. Head and Neck, 37, 594-604. https://doi.org/10.1002/hed.23599
[8]
Fearon, K.C.H., et al. (2012) Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways. Cell Metabolism, 16, 153-166. https://doi.org/10.1016/j.cmet.2012.06.011
[9]
Loumaye, A. and Thissen, J.-P. (2017) Biomarkers of Cancer Cachexia. Clinical Biochemistry, 50, 1281-1288. https://doi.org/10.1016/j.clinbiochem.2017.07.011
[10]
Berardi, E., Madaro, L., Lozanoska-Ochser, B., et al. (2021) A Pound of Flesh: What Cachexia Is and What It Is Not. Diagnostics (Basel), 11, 116. https://doi.org/10.3390/diagnostics11010116
[11]
Dev, R. (2019) Measuring Cachexia-Diagnostic Criteria. Annals of Palliative Medicine, 8, 24-32. https://doi.org/10.21037/apm.2018.08.07
[12]
McDonald, J.J., Fallon, M.T. and Laird, B.J.A. (2019) Meaningful Measures in Cancer Cachexia: Implications for Practice and Research. Current Opinion in Supportive and Palliative Care, 13, 323-327. https://doi.org/10.1097/SPC.0000000000000472
[13]
Castillo-Martínez, L., Castro-Eguiluz, D., et al. (2018) Nutritional Assessment Tools for the Identification of Malnutrition and Nutritional Risk Associated with Cancer Treatment. Revista de investigación clínica, 70, 121-125. https://doi.org/10.24875/RIC.18002524
[14]
Bhuachalla, é.B.N., et al. (2018) Computed Tomography Diagnosed Cachexia and Sarcopenia in 725 Oncology Patients: Is Nutritional Screening Capturing Hidden Malnutrition? Journal of Cachexia, Sarcopenia and Muscle, 9, 295-306. https://doi.org/10.1002/jcsm.12258
[15]
Aziz, E.F., et al. (2011) Malnutrition as Assessed by Nutritional Risk Index Is Associated with Worse Outcome in Patients Admitted with Acute Decompensated Heart Failure: An ACAP-HF Data Analysis. Heart International, 6, e2. https://doi.org/10.4081/hi.2011.e2
[16]
Veterans Affairs Total Parenteral Nutrition Cooperative Study Group (1991) Perioperative Total Parenteral Nutrition in Surgical Patients. The New England Journal of Medicine, 325, 525-532. https://doi.org/10.1056/NEJM199108223250801
[17]
Buzby, G.P., et al. (1988) A Randomized Clinical Trial of Total Parenteral Nutrition in Malnourished Surgical Patients: The Rationale and Impact of Previous Clinical Trials and Pilot Study on Protocol Design. The American Journal of Clinical Nutrition, 47, 357-365. https://doi.org/10.1093/ajcn/47.2.357
[18]
Thieme, R.D., et al. (2013) Nutritional Risk Index Is Predictor of Postoperative Complications in Operations of Digestive System or Abdominal Wall? Arquivos Brasileiros de Cirurgia Digestiva, 26, 286-292. https://doi.org/10.1590/S0102-67202013000400007
[19]
World Health Organization (2021) Body Mass Index BMI. http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi
[20]
Aaronson, N., et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. Journal of the National Cancer Institute, 85, 365-376. https://doi.org/10.1093/jnci/85.5.365
[21]
Singer, S., et al. (2015) Measuring Quality of Life in Patients with Head and Neck Cancer: Update of the EORTC QLQ-H&N Module, Phase III. Head Neck, 37, 1358-1367. https://doi.org/10.1002/hed.23762
[22]
Singer, S., et al. (2019) International Validation of the Revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. Head Neck, 41, 1725-1737. https://doi.org/10.1002/hed.25609
[23]
Giesinger, J., et al. (2016) Replication and Validation of Higher Order Models Demonstrated That a Summary Score for the EORTC QLQ-C30 Is Robust. Journal of Clinical Epidemiology, 69, 79-88. https://doi.org/10.1016/j.jclinepi.2015.08.007
[24]
Jager-Wittenaar, H., et al. (2007) Critical Weight Loss in Head and Neck Cancer—Prevalence and Risk Factors at Diagnosis: An Explorative Study. Support Care Cancer, 15, 1045-1050. https://doi.org/10.1007/s00520-006-0212-9
[25]
Righini, C.-A., et al. (2013) Assessment of Nutritional Status at the Time of Diagnosis in Patients Treated for Head and Neck Cancer. European Annals of Otorhinolaryngology, Head and Neck Diseases, 130, 8-14. https://doi.org/10.1016/j.anorl.2012.10.001
[26]
Martín Villares, C., et al. (2004) Heavy Alcohol Intake, Malnutrition and Head and Neck Cancer Patients. Nutricion Hospitalaria, 19, 348-352.
[27]
Jager-Wittenaar, H., et al. (2017) High Prevalence of Cachexia in Newly Diagnosed Head and Neck Cancer Patients: An Exploratory Study. Nutrition, 35, 114-118. https://doi.org/10.1016/j.nut.2016.11.008
[28]
Nishikawa, D., et al. (2018) The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma. ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties, 80, 1-9. https://doi.org/10.1159/000485515
[29]
Ali, S. and Garcia, J.M. (2014) Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options. Gerontology, 60, 294-305. https://doi.org/10.1159/000356760
[30]
Liguori, I., et al. (2018) Sarcopenia: Assessment of Disease Burden and Strategies to Improve Outcomes. Clinical Interventions in Aging, 13, 913-927. https://doi.org/10.2147/CIA.S149232
[31]
Charles, K.A., et al. (2016) Systemic Inflammation Is an Independent Predictive Marker of Clinical Outcomes in Mucosal Squamous Cell Carcinoma of the Head and Neck in Oropharyngeal and Non-Oropharyngeal Patients. BMC Cancer, 16, 124. https://doi.org/10.1186/s12885-016-2089-4
[32]
Mahmoud, F.A. and Rivera, N.I. (2002) The Role of C-Reactive Protein as a Prognostic Indicator in Advanced Cancer. Current Oncology Reports, 4, 250-255. https://doi.org/10.1007/s11912-002-0023-1
[33]
Duffy, S.A., et al. (2008) Interleukin-6 Predicts Recurrence and Survival among Head and Neck Cancer Patients. Cancer, 113, 750-757. https://doi.org/10.1002/cncr.23615
[34]
Andersson, B.-Å., et al. (2014) Plasma Tumor Necrosis Factor-α and C-Reactive Protein as Biomarker for Survival in Head and Neck Squamous Cell Carcinoma. Journal of Cancer Research and Clinical Oncology, 140, 515-519. https://doi.org/10.1007/s00432-014-1592-8
[35]
Yoshida, T., et al. (2013) Molecular Mechanisms and Signaling Pathways of Angiotensin II-Induced Muscle Wasting: Potential Therapeutic Targets for Cardiac Cachexia. The International Journal of Biochemistry & Cell Biology, 45, 2322-2332. https://doi.org/10.1016/j.biocel.2013.05.035
[36]
Visser, M., et al. (2002) Relationship of Interleukin-6 and Tumor Necrosis Factor-Alpha with Muscle Mass and Muscle Strength in Elderly Men and Women: The Health ABC Study. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 57, M326-M332. https://doi.org/10.1093/gerona/57.5.M326
[37]
Manole, E., et al. (2018) Myokines as Possible Therapeutic Targets in Cancer Cachexia. Journal of Immunology Research, 2018, Article ID: 8260742. https://doi.org/10.1155/2018/8260742
[38]
Magee, T.R., et al. (2006) Myostatin Short Interfering Hairpin RNA Gene Transfer Increases Skeletal Muscle Mass. The Journal of Gene Medicine, 8, 1171-1181. https://doi.org/10.1002/jgm.946
[39]
García, P.S., et al. (2010) Brief-Reports: Elevated Myostatin Levels in Patients with Liver Disease: A Potential Contributor to Skeletal Muscle Wasting. Anesthesia & Analgesia, 111, 707-709. https://doi.org/10.1213/ANE.0b013e3181eac1c9
[40]
White, T.A. and LeBrasseur, N.K. (2014) Myostatin and Sarcopenia: Opportunities and Challenges—A Mini-Review. Gerontology, 60, 289-293. https://doi.org/10.1159/000356740
[41]
Velikova, G., et al. (2012) Health-Related Quality of Life in EORTC Clinical Trials—30 Years of Progress from Methodological Developments to Making a Real Impact on Oncology Practice. European Journal of Cancer—Supplement, 10, 141-149. https://doi.org/10.1016/S1359-6349(12)70023-X
[42]
Bjordal, K., et al. (1999) Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. Journal of Clinical Oncology, 17, 1008-1019. https://doi.org/10.1200/JCO.1999.17.3.1008
[43]
Bjordal, K. and Kaasa, S. (1992) Psychometric Validation of the EORTC Core Quality of Life Questionnaire, 30-Item Version and a Diagnosis-Specific Module for Head and Neck Cancer Patients. Acta Oncologica, 31, 311-321. https://doi.org/10.3109/02841869209108178
[44]
Husson, O., et al. (2020) The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real-World”: Results from the Population-Based PROFILES Registry. Oncologist, 25, e722-e732. https://doi.org/10.1634/theoncologist.2019-0348
[45]
Kasper, B. (2020) The EORTC QLQ-C30 Summary Score as a Prognostic Factors for Survival of Patients with Cancer: A Commentary. Oncologist, 25, e610-e611. https://doi.org/10.1634/theoncologist.2019-0749